.jpg?format=webp&width=780)
This study compared the therapeutic potential of an α-PD-L1 antibody with the CDK4/6 inhibitor abemaciclib in two preclinical mouse models of dMMR cancer, focusing on the immune-modulatory effects of either treatment. Therapeutic effects were accompanied by increasing tumour-infiltrating CD4+/CD8+ T-cells and lower numbers of M2 macrophages. In Mlh1−/− tumours, abemaciclib suppressed the PI3K/Akt pathway and led to the induction of Mxd4/Myc. The immune-modulatory potential of abemaciclib renders this compound ideal for dMMR patients not eligible for ICI treatment.
Like
Save
Share